Elton Dajti
@EltonDajti
Followers
156
Following
132
Media
1
Statuses
83
Joined May 2022
Check out our latest review on intrahepatic cholestasis of pregnancy for @DiseasePrimers @NaturePortfolio
Our NEW Primer on Intrahepatic cholestasis of pregnancy is live today! By Dajti, Tripodi, Hu, Estiù, Shan, Mazzella&Azzaroli. Check it out here:
1
0
0
🇳🇱 Join us at #EASL2025 in Amsterdam 🇳🇱 📅 Thu 08 May 08:30–09:45 | Future of Hepatology: Endohepatology 10:00–10:30 | Baveno @ EASL Track Hub (Cirrhosis & Complications) 📅 Fri 09 May 12:00–13:30 | Baveno General Assembly (Room D201, members only) #LiverTwitter
1
7
25
New research - Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia: interim results from the ATTENTION RCT https://t.co/UR77oV2DIw
#LiverTwitter #MedTwitter
0
10
23
What’s the best way to implement the 2-step clinical care pathway for evaluating MASLD? Is it as effective as VCTE for all patients? Check out this paper in J Hep: https://t.co/kE14CUXC1A. Congrats to @TerryYip12 and the VCTE-Prognosis Study Team! 🎉 #MASLD #ClinicalResearch
2
18
37
🚨 It is finally here‼️ 📜 Carvedilol vs. Propranolol for preventing decompensation and mortality in compensated & decompensated cirrhosis 📎 https://t.co/kt0v8wz9et 🫂 Huge thanks to all coauthors! 🙌
8
132
322
Honored to share our recently published paper in @NatureMedicine🔥shedding light on MASLD heterogeneity #LiverTwitter @AASLDtweets @EASLnews 🗝️2 types of at-risk MASLD: same liver histology, distinct clinical trajectories and biological profiles 👉 https://t.co/w7V3OJPTU5
nature.com
Nature Medicine - Partitioning clustering based on clinical variables applied to multiple patient cohorts identifies two subtypes of metabolic dysfunction-associated steatotic liver disease with...
10
20
73
Congratulations on this important trial @drsuniltaneja
🔑Nutrition is so important in Liver disease. 🔥Hot off the press ✅ACLF-Intensive Nutrition improves survival & frailty ✅MELD & AARC ⬇️ ⬇️ Hospitalization rates 👇👇👇Clinical Gastroenterology & Hepatology doi: 10.1016/j.cgh.2024.09.021.
0
0
3
Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver Disease | NEJM Evidence
evidence.nejm.org
Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter stud...
0
17
54
🚨🚨Happy to share our last paper!!!🚨🚨 Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort - Journal of Hepatology
5
20
47
What a week for non-invasive tests and portal hypertension! Excellent study and congratulations to @MattiasMandorf1 and @mathiasjachs for coordinating this landmark study!
Non-Invasive CSPH Estimated Risk (NICER) model including @Echosens SSM by VCTE at 100Hz 👉Developed (2020-2022) & validated (2023) in contemporary pts. 👉Outperforms ANTICIPATE(-NASH): AUC consistently >0.9. 👉Well-calibrated. 👉Sets a new standard IMHO. #LiverTwitter 🔗👇
1
2
9
🚨#livertwitter
#SpleenStiffness Measurement #SSM by dedicated 100Hz #VCTE #Fibroscan probe improves #PortalHypertension risk assessment 🎯 #NICER model by @mathiasjachs @MattiasMandorf1 for the @BavenoCoop published @LancetGastroHep 📕 https://t.co/eZ5GRrhLzC
4
23
62
1
0
3
🟠Current models (LSM+PLT): grey zone (40-50%), >50% pts have CSPH and decompensate (10%) 🟢Endoscopy in inconclusive cases to diagnose varices: grey zone ⬇️ 22%, excellent prognostication 🔵Validation: SSM = endoscopy in the grey zone, a fully non-invasive approach is possible!
1
0
5
Can we start NSBBs based only on non-invasive tests?🤔 🔥 Check out our new paper addressing this issue in the unique PREDESCI trial cohort 🔥 Thank you @docberza and @jaumebosch9 for the opportunity to work with this wonderful study group @BavenoCoop
journal-of-hepatology.eu
Whether non-invasive tests (NITs) can accurately select patients with cirrhosis requiring non-selective beta-blockers (NSBBs) for clinically significant portal hypertension (CSPH) and prevention of...
3
13
49
Thrilled to have this work out in @HEP_Journal ! Short version: The problem - it’s hard to diagnose minimal HE or predict future overt HE in clinic What we found - automated speech analysis can do both
4
27
89
Homozygosity for the PNPLA3 risk allele is linked to liver fat accumulation. In phase 1 trials, JNJ-75220795, a hepatocyte-targeted GalNAc-conjugated PNPLA3 siRNA, reduced liver fat in PNPLA3 I148M homozygous patients with MAFLD. Full correspondence: https://t.co/kzGJ9AFzk1
0
6
22
Alcohol intake is key to determining prognosis in alcohol-related liver disease, but measuring intake is challenging! Is PEth the best tool, or does self-reporting still matter? @JHEP_Reports @Emil_deleuran @AleksanderKrag
https://t.co/DROznG3FdQ
2
14
41
The authors of today's #readoftheweek📚discuss how sarcopenia on computed tomography is associated with a 2-fold higher risk of mortality in patients with cirrhosis. Read here this @JHEP_Reports article: https://t.co/oGvgKVMthU 🙏 @EltonDajti, @docberza, @RodriguesSu24,
0
10
18